Ancilia Biosciences Secures $4.2 Million in Financing to Advance CRISPR-Based Bacterial Therapies
Ancilia Biosciences, a pioneering biotechnology firm specializing in harnessing CRISPR technology for bacterial therapies, announced today the successful closure of an $4.2 million financing round. Safar Partners led the investment, joined by Metaplanet, Psymed Ventures, Zubi Capital, Spacecadet Ventures, and other institutional and private investors. The funding underscores the company’s commitment to leveraging CRISPR’s natural…